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Available online 29 August 2015AbstractObjectives: Many osteoporosis drugs reliably increase bone mass in the elderly; if these drugs also had a positive effect on muscle, their benefit
would be even greater. We examined the effect of alendronate monotherapy on muscle mass in patients with osteoporosis.
Methods: In this retrospective cohort, case-control study, patients from an osteoporosis database were divided into 2 groups: alendronate-treated
patients (group A; n ¼ 199) and a control group receiving no drug treatment (group C; n ¼ 233). Appendicular skeletal muscle mass (ASM) and
skeletal muscle mass index (SMI) measured by dual-energy X-ray absorptiometry were assessed at approximately 1 year. The change in muscle
mass was compared between the groups.
Results: At baseline, group A included more women and had lower height, weight, bone mineral content, and muscle mass than group C. A
comparison of changes after 1 yeardadjusted for age, sex, observation period, body mass index and initial valuesdrevealed that the muscle
mass in group A showed increases by 0.137 kg/m2 in SMI, 514 g in ASM, and 319 g in lower limb muscle mass (LLM). Group C showed no
changes in muscle mass. A significant difference in the amount of change in ASM and LLM was found between the groups after adjustment: 2.5
times and 4.4 times higher, respectively, in groups A and C. However, the difference in SMI disappeared after adjustment.
Conclusions: This is the first study to show that alendronate may have a positive effect not only on bone, but on muscle as well.
Copyright © 2015 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Muscle decline with age is a well-known cause of
decreased walking ability and is a major factor in restricted
activities of daily living in the elderly. Sarcopenia, defined as a
syndrome that causes physical disability because of decreased
muscle mass and strength, leads to reduced quality of life and* Corresponding author. Department of Orthopedic Surgery, National Center
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ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).death [1,2]. The international agreement by the European
Working Group on Sarcopenia in Older People states that
sarcopenia should be diagnosed using walking ability, muscle
strength, and muscle mass, and that judgments on the need for
intervention can be made from walking ability and muscle
mass levels [3]. The most basic underlying criterion for
diagnosis is muscle mass, however [3,4].
Despite the importance placed on muscle mass, reports on
drugs that have an effect on muscle mass are limited to
testosterone [5e7], angiotensin-converting enzyme inhibitors
[8], statins [9,10], and a few others [11]. Moreover, most of
these drugs have problems in terms of effect and safety reli-
ability, and there are no drugs that can be used regularly inhosting by Elsevier B.V. This is an open access article under the CC BY-NC-
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crease bone mass and contribute to reducing the risk of frac-
ture in the elderly [12]. If these osteoporosis drugs were also to
have a positive effect on muscle mass, their benefit would be
even greater and would be of more value to patients. Vitamin
D preparations may increase both bone and muscle mass
[13,14], but a consistent assessment of their efficacy on muscle
mass has not been reported [11]. To our knowledge, the effect
of bisphosphonates has not been investigated; therefore, we
examined the effect of alendronate monotherapy on muscle
mass in osteoporosis patients.
2. Materials and methods
The study design was a case-control study with a retro-
spective cohort. In our hospital, dual-energy X-ray absorpti-
ometry (DXA) bone density measurements of the lumbar
spine, hip, and total body have been done since the hospital
acquired a DXA machine (DXP-NT; GE Medical Systems
Lunar, Madison, WI, USA). Using total body bone measure-
ments in addition to total bone mineral content (BMC) and
total fat mass (FM), the appendicular skeletal muscle mass
(ASM), which correlates most closely with muscle mass, and
skeletal muscle mass index (SMI), a corrected value for
physique based on the individual's height, can be calculated
[15]. Lower limb muscle mass (LLM) can also be obtained.
Between April 1992 and May 2011, body composition was
measured by DXA in 5999 patients and osteoporosis drugs
were prescribed to 33,734 patients, of whom 1283 were
diagnosed with osteoporosis and included in a database. After
excluding those patients who used other drugs, those who
received combination therapy, and those assessed by DXA forNo. in Osteoporosis
1,283
No. Received 
Alendronate Alone  
264 
No
D
No. Excluded 
65
No. re-assessed with DXA at 
less than 6 months: 7 
No. re-assessed with DXA at 
18 months or more: 58  
No. Treated with 
Alendronate Alone for 1 
Year and Assessed with 
DXA: 199 
D
Fig. 1. Flow diagram of subject selection. Patients receiving alendronate monothera
could be measured with total body DXA for 1 year were extracted from an osteopless than 6 months or more than 1.5 years, 199 patients treated
with alendronate monotherapy (35 mg or 5 mg, both doses
approved by the Ministry of Health, Labour and Welfare in
Japan) for 1 year and evaluated by DXA (group A) and a
control group of 233 patients who received no drug therapy for
1 year also observed with DXA only (group C) were selected
(Fig. 1). These 2 groups are the subjects of this analysis.
Sarcopenia was judged based on SMI only because full data
on walking ability and muscle strength were not available.
Patients with levels below the Japanese criteria (men 6.87 kg/
m2, women 5.46 kg/m2) [16] were diagnosed as having sar-
copenia and patients with levels above those values were not.
The main outcome variables were skeletal muscle mass (ASM,
SMI and LLM).
Statistical analysis was determined using SAS, version 9.2
(SAS Institute Inc.); p < 0.05 indicated significance. The
amount of change in response variables was compared be-
tween the 2 groups. Differences in the amount of change after
1 year were determined using a general linear model with
correction for age, sex, observation period, body mass index
(BMI), and initial value for each item. Secondary analyses
included the correlation between the amount of change in
muscle and other body components after 1 year and the dif-
ference in the amount of change in muscle in patients
receiving 35 mg and 5 mg of alendronate.
This study was approved by the Institutional Review Board.
Its approval number is No. 687-2.
3. Results
A comparison of patient baseline characteristics showed no
difference in mean age (72.4 years) between the groups. Group Database 
No. Excluded 
428
No. received osteoporosis drug 
other than alendronate: 326 
(risedronate: 60, raloxifene: 59, 
alfacalcidol: 52, Other: 155).  
No. received alendronate 
combined with other drug: 102 
. Did Not Receive 
rug Intervention 
591 
No. Excluded 
358  
No. re-assessed with DXA at 
less than 6 months: 73 
No. re-assessed with DXA at 
18 months or more: 285  
No. Did Not Receive 
rug Intervention for 
1 Year; Assessed 
with DXA Only: 233
py and those who were untreated and in whom changes in muscle-related items
orosis database. DXA: dual-energy X-ray absorptiometry; no.: number.
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lower height and body weight. However, there was no differ-
ence in BMI. In addition, group A patients had lower SMI,
ASM, and LLM than group Cdin addition to less change in
muscle mass and lower BMCdbut there was no difference in
FM. At baseline, 77 patients (38.7%) in group A had a diag-
nosis of sarcopenia versus 75 (32.2%) in group C. The
between-group difference in these percentages was not sig-
nificant (Table 1). Moreover, the mean and standard deviation
(SD) of the observation period was 357.5 (SD 80.2) days in
group A, and 359.9 (SD 89.5) days in group C, with no sig-
nificant difference between the groups.
A comparison of changes without adjustments after 1 year
showed no significant changes in muscle-related SMI, ASM,
and LLM in group A. However, among other body composi-
tion measures, FM increased significantly, but there was no
significant change in BMC. In group C, there were significant
decreases in SMI, ASM, and LLM. On the other hand, FM
increased and BMC decrease significantly. Moreover, there
were significantly different amounts of change in SMI, ASM,
and LLM between the groups (Table 2).
Because there was a difference in the amount of muscle
mass between the groups at baseline, the amount of change at
1 year was compared, with adjustments for age, sex, obser-
vation period, BMI, and the initial value of each item. As a
result, the amount of change at 1 year in group A increased
significantly: by 0.137 kg/m2 in SMI, 514 g in ASM, and
319 g in LLM. FM also increased significantly, but there was
no change in BMC. In group C, FM increased, but there were
no significant changes in other items. The difference in the
amounts of change in ASM and LLM between the groups was
significant even after the adjustments were made. The in-
creases in ASM and LLM were 2.5 times and 4.4 times higher,
respectively, in group A than in group C. However, the dif-
ferences in SMI disappeared after the adjustments were made
(Table 2).
A comparison of the correlation of changes in muscle mass
and other body composition items between the groups during
the year showed that in group A the amounts of change in SMI
and ASM were not associated with BMC (r ¼ 0.105,Table 1
Comparison of baseline characteristics in the 2 groups.
Ale
Baseline characteristics Age, mean (SD), y 72.
Female, no. (%) 182
Height, mean (SD), cm 149
Body weight, mean (SD), kg 47.
BMI, mean (SD), kg/m2 21.
SMI, mean (SD), kg/m2 5.7
ASM, mean (SD), g 12,
LLM, mean (SD), g 969
FM, mean (SD), g 13,
BMC, mean (SD), g 148
Sarcopenia, no. (%) 77
ASM: appendicular skeletal muscle mass; BMC: total bone mineral content; BM
number; SD: standard deviation; SMI: skeletal muscle mass index; ns: not signific
a Between-group comparison by t-test or chi-squared test.p ¼ 0.142 and r ¼ 0.120, p ¼ 0.092, respectively), whereas
there was a weak negative correlation with FM (r ¼ 0.105,
p ¼ 0.142 and r ¼ 0.120, p ¼ 0.092, respectively). In group C,
the amounts of change in SMI and ASM showed weak positive
correlations with BMC (r ¼ 0.197, p ¼ 0.003 and r ¼ 0.249,
p ¼ 0.000, respectively) and very weak negative correlations
with FM (r ¼ 164, p ¼ 0.012 and r ¼ 0.151, p ¼ 0.021,
respectively).
The alendronate doses used in group A were 35 mg once
per week in 91 patients, 5 mg daily in 102 patients, and both in
5 patients. The change in SMI was 0.087 (SD 0.591) kg/m2 in
patients receiving 35 mg and 0.000 (SD 0.518) kg/m2 in pa-
tients receiving 5 mg, showing no statistically significant
difference between the 2. Similarly, the change in ASM was
243 (SD 1353) g in patients receiving 35 mg and 5 (SD
1160) g in patients receiving 5 mg, which also is not signifi-
cantly different.
4. Discussion
This is the first report to suggest that alendronate mono-
therapy may help to maintain muscle mass. Muscle and bone
support independence in the elderly, but decrease with age. As
a result, it is not uncommon for older people to have sarco-
penia and osteoporosis [17,18]. Hip fractures from falls are
considered one of the worst effects of these conditions [19,20].
Alendronate is a well-known osteoporosis drug for which there
is abundant evidence of decreased risk of hip fracture
[21,22]da result of its action in increasing bone massdbut its
clinical effect on muscle has remained unknown. A recent case
cohort study by Park et al. showed increased grip strength with
combination alendronate and calcitriol, but no change in
muscle mass [23]. In our retrospective case-control study,
ASM increased 2.5-fold in patients receiving alendronate
compared with the controls even after adjusting for initial
muscle mass. The increase in LLM was a remarkable 4.4-fold.
Calcitriol, which Park et al. used in combination with
alendronate [23], and other forms of vitamin D have played a
role in increasing bone mass. In addition, vitamin D receptors
in striated muscle may respond to increases in muscle strengthndronate (N ¼ 199) Control (N ¼ 233) Differencea
4 (10.5) 72.4 (11.9) ns
(91.5) 189 (81.1) P ¼ 0.0021
.3 (7.7) 151.4 (9.1) P ¼ 0.011
4 (8.4) 50.1 (11.2) P ¼ 0.005
2 (3.2) 21.7 (3.8) ns
02 (0.757) 6.091 (0.954) P < 0.0001
720 (1976) 14,073 (3085) P < 0.0001
4 (1503) 10,704 (2299) P < 0.0001
119 (5918) 13,161 (7875) ns
6 (321) 1649 (497) P < 0.0001
(38.7) 75 (32.2) ns
I: body mass index; FM: total fat mass; LLM: lower limb muscle mass; no.,
ant.
Table 2
Comparison of amount of change in muscle, bone, and fat in the 2 groups after 1 year with no adjustments, and with adjustments for age, sex, observation period,
BMI, and the initial value of each item.
Alendronate (N ¼ 199)
Difference compared
with baselinea
Control (N ¼ 233)
Difference compared
with baselinea
Difference
between-groupb
Amount of change after 1 year
with no adjustments
Difference in SMI, mean (SD), kg/m2 0.045 (0.039)
nsa
0.102 (0.045)
p ¼ 0.0258a
p ¼ 0.0166b
Difference in ASM, mean (SD), g 121 (88)
nsa
280 (97)
p ¼ 0.0043a
p ¼ 0.0027b
Difference in LLM, mean (SD), g 63 (73)
nsa
237 (69)
p ¼ 0.0007a
p ¼ 0.0029b
Difference in FM, mean (SD), g 572 (182)
p ¼ 0.0019a
346 (164)
p ¼ 0.036a
nsb
Difference in BMC, mean (SD), g 3 (6)
nsa
25 (8)
p ¼ 0.003a
p ¼ 0.0071b
Amount of change after 1 year
with adjustments
Difference in SMI, mean (SD), kg/m2 0.137 (0.763)*
p ¼ 0.0118a
0.050 (0.734)
nsa
nsb
Difference in ASM, mean (SD), g 514 (1751)
p < 0.0001a
208 (1797)
nsa
p ¼ 0.0206b
Difference in LLM, mean (SD), g 319 (1319)
p ¼ 0.0007a
72 (1334)
nsa
p ¼ 0.0143b
Difference in FM, mean (SD), g 934 (3141)
p < 0.0001a
557 (2941)
p ¼ 0.004a
nsb
Difference in BMC, mean (SD), g 11 (144)
nsa
16 (129)
nsa
p ¼ 0.0096b
ASM: appendicular skeletal muscle mass; BMC: total bone mineral content; FM: total fat mass; LLM: lower limb muscle mass; SD: standard deviation; SMI:
skeletal muscle mass index; ns: not significant.
a Difference compared with baseline by paired t-test.
b Between-group comparison by t-test.
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study lacked a control comparison, the level of alendronate's
contribution in their results is difficult to judge. In our study,
although the effect on muscle strength and performance could
not be investigated, it is suggested here for the first time that
even alendronate alone may produce clinical improvements in
muscle mass.
Following are hypotheses for the mechanism by which
muscle mass may improve with alendronate. First is a direct
action: It is possible that alendronate causes a proliferation of
muscle cells or activates muscle metabolism via a direct
pharmacological action on as yet unknown muscle stem cells
or myocytes. With regard to alendronate's direct effect of on
myoblasts, we found in a recent investigation that “alendronate
did not affect the morphology, gene expression, or survival of
terminally differentiated human myotubes, whereas it pre-
vented proliferation and differentiation of undifferentiated
human myogenic cells. It is impossible to exclude the putative
secondary effects of [alendronate] that ameliorate muscle
function.” [26] However, alendronate's contribution to muscle
improvement remains unknown. If alendronate does not bind
strongly to bone mineral [27], but rather that alendronate in
the blood is related to the increased muscle mass in this study,
daily formulations that elevate blood levels with a high fre-
quency would be assumed to have a larger effect on muscle
mass than once-weekly formulations. However, this result was
ruled out because there was no difference between the 2.
Second is the indirect action hypothesis. Alendronate acts
in relation to bone metabolism, based on the well-understoodsuppression of osteoclasts [27]; from this, a secondary muscle
improvement may be derived (e.g., when alendronate reduces
bone resorption, serum calcium levels fall and intact para-
thyroid hormones rise). In addition, serum 1,25-
dihydroxyvitamin D levels similarly transiently increase
from 4 weeks to 24 weeks [28] with alfacalcidol administra-
tion and the previously mentioned increase in muscle mass
resulting from vitamin D would occur [13,14]. Moreover,
alendronate is reported to raise bone strength and lower frac-
ture risk, while also reducing pain, improving activities of
daily living [29] and raising quality of life [30]. Improvement
in activities of daily living may be linked to improved muscle
mass through increased movement. In this investigation,
however, although the amounts of change in muscle and bone
were positively correlated in group C, this significant relation
was lost in group A, a result that does not directly agree with
the second hypothesis.
The first limitation of this study is that the research design
was not a prospective randomized controlled trial but a
retrospective case-control study using an osteoporosis data-
base. Even though all subjects were patients with osteoporosis,
group C, which was observed for 1 year without treatment, had
milder disease than group A. In addition, at baseline, group C
had a naturally higher bone mass than group A. Group C also
had higher values for items related to muscle. To minimize the
effects of these differences, analysis with correction of the
initial values was undertaken for each item. The amount of
change in ASM was significant. The second limitation is that,
because the analysis was conducted in this way, SMI's
57A. Harada et al. / Osteoporosis and Sarcopenia 1 (2015) 53e58significance did not persist. This may also be affected by
multiple inputs of adjusted items, including the square of
height. Third, muscle strength, walking speed, and other per-
formance items in the latest diagnostic criteria for sarcopenia
were not evaluated; therefore, it remains unknown whether
alendronate affects these items. Moreover, vitamin D and
substances that are possible muscle markers were not
measured; therefore, the range of the analysis was limited to
changes in body composition. Consequently, the suggestions
obtained in this study will need to be confirmed in a ran-
domized controlled trial in which these issues are resolved. In
addition, muscle and bone mass could be affected by several
factors, such as physical activity, pain, and the underlying
diseases. However, we could not obtain such information from
our database, and therefore, this is also limitation of the cur-
rent study.
In conclusion, our retrospective case-control study showed
that ASM increased 2.5-fold with alendronate compared with
the controls, even after adjusting for initial muscle mass. The
increase in LLM was a remarkable 4.4-fold. This is the first
study to show the possibility that alendronate monotherapy has
a positive effect not only on bone but also on muscle.
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